Boolean ErbB network reconstructions and perturbation simulations reveal individual drug response in different breast cancer cell lines

BACKGROUND: Despite promising progress in targeted breast cancer therapy, drug resistance remains challenging. The monoclonal antibody drugs trastuzumab and pertuzumab as well as the small molecule inhibitor erlotinib were designed to prevent ErbB-2 and ErbB-1 receptor induced deregulated protein si...

Descripción completa

Detalles Bibliográficos
Autores principales: der Heyde, Silvia Von, Bender, Christian, Henjes, Frauke, Sonntag, Johanna, Korf, Ulrike, Beißbarth, Tim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4087127/
https://www.ncbi.nlm.nih.gov/pubmed/24970389
http://dx.doi.org/10.1186/1752-0509-8-75

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4087127/
https://www.ncbi.nlm.nih.gov/pubmed/24970389
http://dx.doi.org/10.1186/1752-0509-8-75

Ejemplares similares